Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Telavancin Clear all
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

NCT01321879
View directory record Official record
Conditions
Infection, Bacteremia
Interventions
Telavancin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 20, 2026, 1:56 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

NCT00061633
View directory record Official record
Conditions
Infections, Gram-Positive Bacterial, Abscess, Burns, Cellulitis, Ulcer, Wound Infections
Interventions
Telavancin, Vancomycin or antistaphylococcal penicillin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 20, 2026, 1:56 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

NCT00107952
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Telavancin, Vancomycin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
761 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 20, 2026, 1:56 PM EDT
Completed Phase 4 Interventional Results available

Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5

NCT02392208
View directory record Official record
Conditions
End-Stage Renal Disease, Stage 5 Chronic Kidney Disease
Interventions
Telavancin, Pharmacokinetic Blood Sampling
Drug · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 20, 2026, 1:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin

NCT01238796
View directory record Official record
Conditions
Kidney Diseases, End Stage Renal Disease
Interventions
telavancin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 20, 2026, 1:56 PM EDT
Completed Phase 2 Interventional Results available

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

NCT00062647
View directory record Official record
Conditions
Gram-Positive Bacterial Infections
Interventions
Telavancin, Vancomycin, nafcillin, oxacillin, or cloxacillin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 20, 2026, 1:56 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

NCT00077675
View directory record Official record
Conditions
Infections, Gram-positive Bacterial
Interventions
Telavancin, vancomycin or antistaphylococcal penicillin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 20, 2026, 1:56 PM EDT
Recruiting Phase 4 Interventional

Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage

NCT06119061
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
Telavancin Injection
Drug
Lead sponsor
Aaron Cook
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 20, 2026, 1:56 PM EDT
Withdrawn No phase listed Observational

VIBATIV Pregnancy Registry

NCT01130324
View directory record Official record
Conditions
Pregnancy
Interventions
VIBATIV
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 20, 2026, 1:56 PM EDT
Terminated Phase 1 Interventional Results available

Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)

NCT02013141
View directory record Official record
Conditions
Gram-Positive Bacterial Infections
Interventions
Telavancin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
12 Months to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
7
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 20, 2026, 1:56 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

NCT02208063
View directory record Official record
Conditions
Bacteremia
Interventions
Telavancin, Vancomycin, Daptomycin, Synthetic penicillin, Cefazolin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 20, 2026, 1:56 PM EDT
Completed Phase 4 Interventional

Telavancin Pharmacokinetics in Cystic Fibrosis Patients

NCT03172793
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Telavancin Injection
Drug
Lead sponsor
Joseph L. Kuti, PharmD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Hartford, Connecticut • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Oct 20, 2026, 1:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Telavancin in Normal and Obese Subjects

NCT02753855
View directory record Official record
Conditions
Healthy
Interventions
Telavancin
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 20, 2026, 1:56 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

NCT00091819
View directory record Official record
Conditions
Staphylococcal Skin Infection
Interventions
Telavancin, Vancomycin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 20, 2026, 1:56 PM EDT
Completed No phase listed Observational

Telavancin Observational Use Registry (TOUR)

NCT02288234
View directory record Official record
Conditions
Hospital Acquired Bacterial Pneumonia, Complicated Skin and Skin Structure Infections, Ventilator Associated Bacterial Pneumonia, Gram Positive Infection
Interventions
Vibativ
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
1,063 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 20, 2026, 1:56 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

NCT00107978
View directory record Official record
Conditions
Staphylococcal Skin Infection
Interventions
Telavancin, Vancomycin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 20, 2026, 1:56 PM EDT